Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
IMMURON LIMITED (IMC)ASX AI Signals has generated 3 signal for IMC during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest IMC Signals | |
| 18/05/2026 | BUY |
| 17/05/2026 | BUY |
| 16/05/2026 | BUY |
IMC Share Price | |
| Current Price | $0.036 |
| 52 Week High | $0.094 |
| 52 Week Low: | $0.026 |
| Trading at (% of 52 Week High) | 38.30% |
Immuon Limited (ASX: IMC) is a biopharmaceutical company focused on developing oral immunotherapy treatments for infectious and chronic diseases. The company specializes in leveraging antibody-based therapies to target gastrointestinal and inflammatory conditions.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for IMMURON LIMITED (IMC) is supported by potential upside at a low price point, but overall confidence remains low due to limited liquidity, high volatility, and lack of strong fundamental catalysts.
Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for fiscal year 2025. It stated that much of the growth was due to robust sales of its flagship travele Shares of Immuron Ltd. rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million Gainers
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACRLatest IMMURON LIMITED(IMC) News
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales
Immuron stock rockets after funding by U.S. DoD of new research agreement
18 Stocks Moving in Friday's Pre-Market Session
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial